RxDoctor Payments Data

Daniel Branovan, MD

Surgery · Brooklyn, NYNPI 1235198250

Payments from drug & device makers

$2,096in general payments, 2019–2025

Across 75 payments — averaging $27.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$402
  • Sanofi$335
  • Medtronic$300
  • GSK$257
  • Optinose US, Inc.$190
  • Intersect ENT, Inc.$171
  • plus $441 from 8 others

What the payments were for

  • Food & beverage$2,096100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,096 in reported general payments places this provider in the 55th percentile of 1,596 surgery providers in New York.

See all surgery providers in New York

Medicare billing

Part B allowed, 2024
$717,485
Medicare patients
1,635
Services billed
4,652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab19$69,416
Sodium ChlorideSodium Chloride Irrig Solution1,521$45,381
Ipratropium Bromide702$17,298
Fluticasone Propionate2,101$15,835
Famotidine1,180$11,296
Dexlansoprazole DrDexlansoprazole31$10,223
Mupirocin1,199$6,130
Tobramycin-DexamethasoneTobramycin/Dexamethasone134$5,538
Gentamicin Sulfate189$3,694
RyaltrisOlopatadine Hcl/Mometasone13$3,071
Azelastine Hcl153$2,865
CefuroximeCefuroxime Axetil115$2,431
Mometasone Furoate103$2,400
Pantoprazole Sodium266$2,344
Cefdinir154$2,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USARyaltris$47$3,07113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,596 surgery providers in New York.

Other surgery in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →